Life Science Today

Originally Published as The Niche Podcast

Genentech’s next tech, GSK divests to invest, Bristol Myers Squibb checks oncology, Cassava Sciences raises capital, Libtayo gets expanded FDA approval, and Hyperfine turns on hyperdrive. 

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-34-1
https://tinyurl.com/Niche-34-2
https://tinyurl.com/Niche-34-3
https://tinyurl.com/Niche-34-4
https://tinyurl.com/Niche-34-5
https://tinyurl.com/Niche-34-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Two Mercks - three stories, Paraxel gets genomes, Genomes get Money, and 2021 is the year of the upsized public offering.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-33-Merck1
https://tinyurl.com/Niche-33-Merck2
https://tinyurl.com/Niche-33-Merck3
https://tinyurl.com/Niche-33-2
https://tinyurl.com/Niche-33-3
https://tinyurl.com/Niche-33-4
https://tinyurl.com/Niche-33-5
https://tinyurl.com/Niche-33-6 

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Biogen gets punted but it’s good, lupus breakthroughs, Senseonics raises capital, and Novavax and Johnson & Johnson… and Janssen.


Sponsors
https://www.thescopemethod.com


Story References
https://tinyurl.com/Niche-032-1
https://tinyurl.com/Niche-032-2
https://tinyurl.com/Niche-032-3
https://tinyurl.com/Niche-032-4
https://tinyurl.com/Niche-032-5


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This is our January interview bonus. I sit down with John Reites, founder and CEO of Thread Research to discuss eCOA, decentralized clinical trials past, present, and future, and how you can think about a decentralized approach to your project.

 
Timeline

1:00 – The last 10 years of decentralized research

3:15 – The current regulatory landscape and variability in the industry

5:32 – Moving into the life sciences from another spaces 

8:28 – Breakdown of eCOA and the subcategories you need to know about 

12:36 – Are all trials becoming decentralized? 

15:40 – Decentralized trials in the future

22:04 – Data Security with eCOA and decentralized trials   

25:58 – Challenges implementing international and multinational decentralized trials 

32:00 – Steps you should take to make your trial decentralized-ready 

Sponsors
https://www.thescopemethod.com

More on John Reites
https://www.threadresearch.com

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Thermo Fisher Scientific spends a billion, Boston Scientific also spends a billion and gets FDA approval, Verve pulls $94 million for CRISPR in humans, and Vera raises $80 million for Berger’s disease



Sponsors
https://www.thescopemethod.com


Story References
https://tinyurl.com/Niche030-1
https://tinyurl.com/Niche030-2
https://tinyurl.com/Niche030-3
https://tinyurl.com/Niche030-4


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

100 million vaccines, EvoQ’s NanoDisk, Merck gets FDA priority, and startups in wearables, startups in diagnostics.


Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche029-1
https://tinyurl.com/Niche029-2
https://tinyurl.com/Niche029-3
https://tinyurl.com/Niche029-4

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Turning CAR T on and off, Fujifilm’s $2 billion investment, Affinivax raises $226 million, and startups to watch



Sponsors
https://www.thescopemethod.com

Story References
10.1126/scitranslmed.abb6295
https://affinivax.com/affinivax-announces-226-million-series-c-financing-to-advance-its-pipeline-of-novel-maps-vaccines-targeting-infectious-diseases/
https://www.fujifilm.com/us/en/news/Fujifilm_to_Invest_2B_for_Cell_Culture_Manufacturing_Site
https://www.businesswire.com/news/home/20210105005224/en/IconOVir-Bio-Raises-77-Million-in-Series-A-Financing-to-Develop-Next-Generation-Oncolytic-Viruses-to-Treat-Solid-Tumors
https://www.lexeotx.com/
 

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

AstraZeneca and W.H.O., vaccine I-told-you-so’s, Phitonex acquired by ThermoFisher, and Axsome reports success in migraine relief. 

Sponsors
https://www.thescopemethod.com

Story References
https://www.rttnews.com/3157074/astrazeneca-s-covid-19-vaccine-cleared-by-expert-panel-in-india.aspx?refresh=1
https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
https://www.bbc.com/news/health-55280671
https://thermofisher.mediaroom.com/2020-12-31-Thermo-Fisher-Scientific-Acquires-Programmable-Dye-Platform-Pioneer-Phitonex
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-positive-efficacy-and-safety-0?field_nir_news_date_value[min]=

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Trends in science from investors and immune-oncology to decentralized trials and basic research, we look back on 2020



Sponsors
https://www.thescopemethod.com

Story References
www.thenichepod.com

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

COVID updates, ERT & Bioclinica merge, Philips acquires BioTelemetry, and augmented reality surgeries.

Sponsors
https://www.thescopemethod.com


Story References
https://www.ellumehealth.com/2020/12/15/fda-authorizes-ellume-covid-19-home-test-as-first-over-the-counter-fully-at-home-diagnostic-test/
Wang et al., 2019 - https://pubs.acs.org/doi/10.1021/acsomega.9b00657
https://www.ert.com/featured-news/ert-and-bioclinica-to-merge-creating-a-global-leader-in-clinical-trial-endpoint-technology/
https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html
https://www.prnewswire.com/news-releases/seeing-is-believing-hospital-for-special-surgery-first-in-us-to-use-augmented-reality-platform-for-knee-replacement-301195275.html


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.